Institute for Clinical Molecular Biology, Christian-Albrechts University of Kiel, Schittenhelmstr. 12, D-24105 Kiel, Germany.
Semin Immunol. 2009 Dec;21(6):334-45. doi: 10.1016/j.smim.2009.10.001. Epub 2009 Nov 17.
Recent advances have enabled a comprehensive understanding of the genetic architecture of inflammatory bowel disease (IBD) with over 30 identified and replicated disease loci. The pathophysiological consequences of disease gene variants in Crohn disease and ulcerative colitis, the two main subentities of IBD, so far are only understood on the single disease gene level, yet complex network analyses linking the individual risk factors into a molecular risk map are still missing. In this review, we will focus on recent pathways and cellular functions that emerged from the genetic studies (e.g. innate immunity, autophagy) and delineate the existence of shared (e.g. IL23R, IL12B) and unique (e.g. NOD2 for CD) risk factors for the disease subtypes. Ultimately, the defined molecular profiles may identify individuals at risk early in life and may serve as a guidance to administer personalized interventions for causative therapies and/or early targeted prevention strategies. Due to this comparatively advanced level of molecular understanding in the field, IBD may represent precedent also for future developments of individualized genetic medicine in other polygenic disorders in general.
近年来,随着 30 多个已确定和复制的疾病位点的出现,人们对炎症性肠病(IBD)的遗传结构有了全面的了解。在克罗恩病和溃疡性结肠炎(IBD 的两个主要亚型)中,疾病基因变异的病理生理后果目前仅在单个疾病基因水平上得到理解,但将单个风险因素链接到分子风险图谱的复杂网络分析仍然缺失。在这篇综述中,我们将重点介绍遗传研究中出现的最近的途径和细胞功能(例如先天免疫、自噬),并描述疾病亚型共享(例如 IL23R、IL12B)和独特(例如 NOD2 用于 CD)风险因素的存在。最终,定义的分子谱可能会在生命早期识别出处于危险中的个体,并可作为指导,为因果治疗和/或早期靶向预防策略实施个性化干预措施。由于该领域在分子理解方面相对先进,IBD 可能为未来个体化遗传医学在其他多基因疾病中的发展提供先例。